Riskpilot← Back to searchSign inGet full accessMetaceutic ApS
APSActiveCVR 40638350Mileparken 22, 2.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20191 employees
Revenue 2025
DKK 1,1M
-2360% vs 2024
EBITDA margin
4.0%
+104% vs 2024
Equity ratio
11.3%
Financial strength
Net profit 2025
DKK 2,4M
+279% vs 2024
| Revenue | DKK 1,1M | -2360% |
| EBITDA | DKK 44K | +104% |
| Net profit | DKK 2,4M | +279% |
| Total assets | DKK 2,4M | +156% |
| Equity | DKK 277K | +113% |
| Employees | 1 | — |
Legal name
Metaceutic ApS
CVR number
40638350
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. juli 2019
Share capital
DKK 2.066.675
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik.
Address
Mileparken 22, 2.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -541 | -2.189 | -987 | -1.183 | -48 | 1.096 |
| Staff expenses | -861 | -2.003 | -790 | -778 | -1.047 | -1.051 |
| EBITDA | -1.403 | -4.192 | -1.777 | -1.961 | -1.096 | 44 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -1.403 | -4.192 | -1.777 | -1.961 | -1.096 | 44 |
| Net financials | -35 | 7 | -25 | -76 | -223 | -2.308 |
| Profit before tax | -1.438 | -4.186 | -1.802 | -2.037 | -1.319 | 2.365 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -1.438 | -4.186 | -1.802 | -2.037 | -1.319 | 2.365 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1.362 | 2.496 | 1.760 | 1.063 | 954 | 2.442 |
| Equity | 602 | 2.066 | 1.268 | -769 | -2.088 | 277 |
| Long-term debt | 0 | 0 | 0 | 1.604 | 2.801 | 1.969 |
| Short-term debt | 760 | 430 | 492 | 228 | 240 | 197 |
| Total debt | 760 | 430 | 492 | 1.831 | 3.042 | 2.165 |
EBITDA margin
4.0%
This company
15.8%
Market median
-75% vs market
20202025
Equity ratio
11.3%
This company
38.2%
Market median
-70% vs market
20202025
Return on equity
854.3%
This company
18.4%
Market median
+4543% vs market
20202025
Net profit margin
215.8%
This company
8.1%
Market median
+2564% vs market
20202025
Asset turnover
0.45×
This company
1.12×
Market median
-60% vs market
20202025
Debt / equity
7.82×
This company
0.62×
Market median
-1161% vs market
20202025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2019-07-04 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AK Management | Management | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
A. Kazemi ApS | Company | 66.7% | 66.7% | 2021 |
Ginnerup Capital ApS | Company | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ginnerup Capital ApS
Metaceutic ApS Board members of Metaceutic ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ali Kazemi Seresht | Management | 0 companies |
| Maria Maibøl Jakobsen | Board of Directors | 0 companies |
| Jakob Saabye-Brøndum | Board of Directors | 0 companies |
| Jan Greve | Chairman | 0 companies |
| Kim Erik Ginnerup | Board of Directors | 0 companies |